© Reuters. FILE PHOTO: A man enters the employee entrance of the Pfizer World Headquarters building in New York

(Reuters) – Pfizer Inc (N:) posted a quarterly profit on Tuesday that came in below Wall Street estimates, as sales of breast cancer drug Ibrance fell short of expectations.

Under Albert Bourla, who took the helm at the start of last year, Pfizer has streamlined operations and announced plans to separate its off-patent branded drugs business, Upjohn, and combine it with generic drugmaker Mylan NV (O:).

The company said it expects 2020 adjusted earnings per share to be in the range $2.82 to $2.92. Excluding Upjohn unit, it expects full-year adjusted earnings in the range $2.25 to $2.35 per share.

Sales of breast cancer drug Ibrance rose 13.2% to $1.28 billion in the fourth quarter, but missed the consensus estimate of $1.35 billion, according to IBES data from Refinitiv.

Revenue fell 9% to $12.69 billion, partly hurt by intense competition for its pain treatment Lyrica that lost patent protection last year.

Excluding items, it earned 55 cents per share, missing the average analyst estimate of 58 cents per share.

Net loss attributable to Pfizer narrowed to $337 million, or 6 cents per share, in the quarter, from $394 million, or 7 cents per share, a year earlier.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link